Douglass Winthrop Advisors LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 2.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 131,280 shares of the company’s stock after acquiring an additional 3,155 shares during the period. Douglass Winthrop Advisors LLC’s holdings in Johnson & Johnson were worth $19,545,000 at the end of the most recent quarter.
Several other large investors have also made changes to their positions in JNJ. Morgan Stanley lifted its holdings in shares of Johnson & Johnson by 0.3% in the 1st quarter. Morgan Stanley now owns 20,801,433 shares of the company’s stock valued at $2,727,694,000 after acquiring an additional 54,563 shares during the last quarter. Vantage Investment Partners LLC lifted its stake in Johnson & Johnson by 6.1% in the second quarter. Vantage Investment Partners LLC now owns 65,444 shares of the company’s stock worth $9,203,000 after purchasing an additional 3,770 shares during the last quarter. Cubic Asset Management LLC lifted its stake in Johnson & Johnson by 6.6% in the second quarter. Cubic Asset Management LLC now owns 44,965 shares of the company’s stock worth $6,323,000 after purchasing an additional 2,785 shares during the last quarter. Stonebridge Financial Planning Group LLC lifted its stake in Johnson & Johnson by 4.0% in the second quarter. Stonebridge Financial Planning Group LLC now owns 2,630 shares of the company’s stock worth $371,000 after purchasing an additional 101 shares during the last quarter. Finally, SPC Financial Inc. increased its position in shares of Johnson & Johnson by 398.6% during the second quarter. SPC Financial Inc. now owns 11,423 shares of the company’s stock worth $1,606,000 after acquiring an additional 9,132 shares during the period. 67.44% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts have issued reports on the stock. Credit Suisse Group lifted their price target on shares of Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a report on Wednesday, October 14th. Raymond James reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Friday, November 20th. Cantor Fitzgerald lifted their price target on shares of Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, October 14th. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday, August 3rd. Finally, Stifel Nicolaus lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, August 19th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $164.93.
NYSE JNJ opened at $143.68 on Friday. The company has a market capitalization of $378.24 billion, a PE ratio of 22.59, a P/E/G ratio of 3.04 and a beta of 0.69. The company has a fifty day moving average of $145.31 and a 200 day moving average of $146.47. Johnson & Johnson has a 1 year low of $109.16 and a 1 year high of $157.00. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.48 and a quick ratio of 1.24.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.98 by $0.22. The company had revenue of $21.08 billion during the quarter, compared to the consensus estimate of $20.15 billion. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The firm’s quarterly revenue was up 1.7% on a year-over-year basis. During the same period in the previous year, the firm posted $2.12 earnings per share. Research analysts expect that Johnson & Johnson will post 7.99 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be given a $1.01 dividend. The ex-dividend date of this dividend is Monday, November 23rd. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.81%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 46.54%.
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,115 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total value of $2,473,974.80. Following the completion of the transaction, the executive vice president now owns 66,658 shares in the company, valued at $10,233,336.16. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.27% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Featured Article: What is a Reverse Stock Split?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.